Frequency of p16INK4A alterations and k-ras mutations in intrahepatic cholangiocarcinoma of the liver

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Gut

• Publication date

  2000-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1136/gut.47.5.721PMID 11034592PMCID PMC1728101
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic epidemiology of mutated K-rasproto-oncogene, altered suppressor genes, and microsatellite instability in colorectal adenomas

  1999cited by this paper
• p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma.

  1999cited by this paper
• High frequency of p16INK4A gene alterations in hepatocellular carcinoma

  1999cited by this paper
• Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras

  1999cited by this paper
• Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma.

  1999cited by this paper
• Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver

  1999cited by this paper
• Expression of catalytically active telomerase does not prevent premature senescence caused by overexpression of oncogenic Ha-Ras in normal human fibroblasts.

  1999cited by this paper
• Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma.

  1999cited by this paper
• Association of K-ras mutations with p16 methylation in human colon cancer.

  1999cited by this paper
• Signaling to Rho GTPases.

  1999cited by this paper
• The INK4 family of cell cycle inhibitors in cancer

  1999cited by this paper
• p16INK4 is inactivated by extensive CpG methylation in human hepatocellular carcinoma

  1999cited by this paper
• Role of the ras-MAPK Signaling Pathway in the DNA Methyltransferase Response to DNA Hypomethylation

  1998cited by this paper
• Mutation spectra resulting from carcinogenic exposure: from model systems to cancer-related genes.

  1998cited by this paper
• Mutation analyses of KRAS exon 1 comparing three different techniques: temporal temperature gradient electrophoresis, constant denaturant capillary electrophoresis and allele specific polymerase chain reaction.

  1998cited by this paper
• Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

  1997cited by this paper
• K-ras mutations in patients with early colorectal cancers

  1997cited by this paper
• Germ‐line mutations of the p16INK4(MTS1) gene occur in a subset of patients with hepatocellular carcinoma

  1997cited by this paper
• p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis.

  1996cited by this paper
• Role of the INK4a locus in tumor suppression and cell mortality.

  1996cited by this paper
• Myristoylation of ADP-ribosylation Factor 1 Facilitates Nucleotide Exchange at Physiological Mg Levels (*)

  1995cited by this paper
• Prognostic Factors in Cancer

  1995cited by this paper
• Inhibition of ras-induced proliferation and cellular transformation by p16INK4

  1995cited by this paper
• Regulation of DNA methylation by the Ras signaling pathway

  1995cited by this paper
• Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance.

  1994cited by this paper
• Germline p16 mutations in familial melanoma

  1994cited by this paper
• Current concepts in metastasis.

  1994cited by this paper
• Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand

  1993cited by this paper
• Activation of the c-Ki-ras oncogene in aflatoxin B1-induced hepatocellular carcinoma and adenoma in the rat: detection by denaturing gradient gel electrophoresis.

  1993cited by this paper

• Transcription Factors as Drivers of Gallbladder Cancer: Mechanisms, Dysregulation, and Therapeutic Prospects

  2025cites this paper
• A New Staining Method Using Methionyl-tRNA Synthetase 1 Antibody for Endoscopic Ultrasound-Guided Fine-Needle Aspiration Cytology of Pancreatic Cancer

  2025cites this paper
• Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Growth in Cholangiocarcinoma

  2024cites this paper
• Noncanonical TRAIL Signaling Facilitates Tumor Immunosuppression and Cholangiocarcinoma Growth via Myeloid-Derived Suppressor Cells

  2023cites this paper
• Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Progression in Cholangiocarcinoma

  2023cites this paper
• Prediction of Prognosis in Pancreatic Cancer According to Methionyl-tRNA Synthetase 1 Expression as Determined by Immunohistochemical Staining

  2023influential citation
• Granulomatous Dermatitis in a Patient With Cholangiocarcinoma Treated With BRAF and MEK Inhibitors.

  2023cites this paper
• Meta-analysis on prognostic value of KRAS mutation in resected mass-forming cholangiocarcinoma.

  2022cites this paper
• Chromosomal aberrations, visualized using UroVysion® fluorescence in-situ hybridization assay, can predict poor prognosis in formalin-fixed paraffin-embedded tissues of cholangiocarcinoma patients.

  2022cites this paper
• DNA methylation in cell plasticity and malignant transformation in liver diseases.

  2022cites this paper
• Intraductal papillary neoplasm of the bile duct: Cytomorphologic and molecular features

  2022cites this paper
• Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer

  2022cites this paper
• Integrated Bioinformatic Analysis Identifies TIPIN as a Prognostic Biomarker in Hepatocellular Carcinoma

  2022cites this paper
• Diagnosis Biomarkers of Cholangiocarcinoma in Human Bile: An Evidence-Based Study

  2022cites this paper
• Cholangiocarcinoma and liver transplantation: What we know so far?

  2021cites this paper
• Optimal tissue sampling during ERCP and emerging molecular techniques for the differentiation of benign and malignant biliary strictures

  2021cites this paper
• Phosphorylation and Stabilization of PIN1 by JNK Promote Intrahepatic Cholangiocarcinoma Growth

  2021cites this paper
• Intrahepatic Cholangiocarcinoma: A Summative Review of Biomarkers and Targeted Therapies

  2021cites this paper
• Oncogenic KRAS–expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice

  2020cites this paper
• Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis – The promise of DNA methylation and molecular biomarkers

  2020cites this paper
• Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine

  2020cites this paper
• In Vivo Models for Cholangiocarcinoma—What Can We Learn for Human Disease?

  2020cites this paper
• Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers

  2019cites this paper
• The promising role of epigenetic mediators and microRNAs in the early diagnosis of cholangiocarcinoma (Review)

  2019cites this paper
• mTOR Inhibitors in Advanced Biliary Tract Cancers

  2019cites this paper
• Epigenomic biomarkers for prognostication and diagnosis of gastrointestinal cancers.

  2019cites this paper
• Kras-driven heterotopic tumor development from hepatobiliary organoids.

  2019cites this paper
• Dependency of Cholangiocarcinoma on Cyclin D–Dependent Kinase Activity

  2019influential citation
• A new staining method using methionyl-tRNA synthetase 1 antibody for brushing cytology of bile duct cancer.

  2019cites this paper
• Emerging role of precision medicine in biliary tract cancers

  2018cites this paper
• Molecular Mechanisms of Cholangiocarcinogenesis: New Potential Targets for Therapy.

  2017cites this paper
• Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population

  2017cites this paper
• Signaling pathways as therapeutic targets in biliary tract cancer

  2017cites this paper
• Mutations of candidate tumor suppressor genes at chromosome 3p in intrahepatic cholangiocarcinoma.

  2017cites this paper
• Elevated AQP1 Expression Is Associated With Unfavorable Oncologic Outcome in Patients With Hilar Cholangiocarcinoma

  2017cites this paper
• Claudin-18 coupled with EGFR/ERK signaling contributes to the malignant potentials of bile duct cancer.

  2017cites this paper
• Circulating copper and zinc levels and risk of hepatobiliary cancers in Europeans

  2017cites this paper
• Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis.

  2017cites this paper
• Evaluation and validation of suitable reference genes for reverse transcription-quantitative polymerase chain reaction studies in cholangiocarcinoma patients and cell lines.

  2016cites this paper
• Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy.

  2016cites this paper
• New genomic landscapes and therapeutic targets for biliary tract cancers.

  2016influential citation
• Molecular genetics and targeted therapeutics in biliary tract carcinoma.

  2016cites this paper
• Targeted Therapeutics against Biliary Cancer Elicit Concurrent Tumor Extrinsic Effects on Immune Suppression and Cancer Cachexia

  2016cites this paper
• A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion

  2016cites this paper
• Growth Regulation in Hepatobiliary Cancer: Regulators of the Cell Division Cycle

  2016cites this paper
• Etiology and Pathogenic Pathways of Cholangiocarcinoma

  2016cites this paper
• Cholangiocarcinoma and Gallbladder Cancer

  2016cites this paper
• Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice.

  2016cites this paper
• Molecular characteristics of biliary tract cancer.

  2016cites this paper
• Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma

  2016cites this paper
• Molecular diagnosis of intrahepatic cholangiocarcinoma

  2015cites this paper
• Next-generation sequencing and personalized genomic medicine in hepatobiliary malignancies.

  2015cites this paper
• Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma

  2015influential citation
• Malignant Transformation in Von-Meyenburg Complexes: Histologic and Immunohistochemical Clues With Illustrative Cases

  2015cites this paper
• Pathogenesis and Therapeutic Targets of Cholangiocarcinoma

  2015cites this paper
• Genetics of Opisthorchis viverrini-related cholangiocarcinoma

  2015cites this paper
• Clinical and biological significance of precursor lesions of intrahepatic cholangiocarcinoma.

  2015cites this paper
• Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways.

  2015cites this paper
• Facteurs pronostiques de survie dans les cholangiocarcinomes intrahépatiques

  2015cites this paper
• Sox9 expression in carcinogenesis and its clinical significance in intrahepatic cholangiocarcinoma.

  2015cites this paper
• Defining the role of Notch signalling in intrahepatic cholangiocarcinoma

  2015cites this paper
• A multistep cytological approach for patients with jaundice and biliary strictures of indeterminate origin

  2015cites this paper
• A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.

  2014cites this paper
• Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine

  2014influential citation
• Capsaicin Treatment Attenuates Cholangiocarcinoma Carcinogenesis

  2014cites this paper
• Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma.

  2014cites this paper
• FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling

  2014cites this paper
• Molecular Targeted Therapy for Biliary Tract Cancer-A Future Perspective

  2014cites this paper
• High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases

  2014cites this paper
• Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets

  2014cites this paper
• Aberrant methylation in promoter region induced silencing of P 16/NK4a in colorectal cancer in Iranian patients

  2014cites this paper
• Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma

  2014cites this paper
• Central JSM Clinical Oncology and Research

  2014cites this paper
• Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology.

  2013cites this paper
• Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

  2013cites this paper
• Adjuvant gemcitabine therapy improves survival in a locally induced, R0‐resectable model of metastatic intrahepatic cholangiocarcinoma

  2013cites this paper
• The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer

  2013cites this paper
• KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas

  2013cites this paper
• Genetic and Epigenetic Abnormalities in Primary Sclerosing Cholangitis-associated Cholangiocarcinoma

  2013cites this paper
• Second-line therapy in advanced biliary tract cancer: what should be the standard?

  2013cites this paper
• Mouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic target

  2013cites this paper
• Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies

  2013cites this paper
• Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma

  2013cites this paper
• Primary Sclerosing Cholangitis and Cholangiocarcinoma: Pathogenesis and Modes of Diagnostics

  2013cites this paper
• The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome.

  2013cites this paper
• New and emerging treatment options for biliary tract cancer

  2013cites this paper
• Molecular Markers of Cholangiocarcinoma

  2013cites this paper
• Activation of Notch Signaling Is Required for Cholangiocarcinoma Progression and Is Enhanced by Inactivation of p53 In Vivo

  2013cites this paper
• Genetic profiling of intrahepatic cholangiocarcinoma

  2012cites this paper
• S100P immunostaining identifies a subset of peripheral‐type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas

  2012cites this paper
• Gene expression and epigenetic changes by furan in rat liver.

  2012cites this paper
• Polysomy and p16 deletion by fluorescence in situ hybridization in the diagnosis of indeterminate biliary strictures.

  2012cites this paper
• Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

  2012cites this paper
• Uncommon Hepatobiliary Tumors

  2012cites this paper
• Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.

  2012cites this paper
• Surgical management of proximal bile duct cancers

  2012cites this paper
• Downregulation of DLC-1 Gene by Promoter Methylation during Primary Colorectal Cancer Progression

  2012cites this paper
• A case of ovarian mucinous adenocarcinoma in a premenarcheal girl

  2012cites this paper
• Anatomisch-pathologische Besonderheiten der Klatskin-Tumoren

  2012cites this paper
• [Pathological anatomical characteristics of Klatskin tumors. Classification, current molecular biological aspects, prognosis factors].

  2012cites this paper